XERS
Xeris Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.04B
P/E Ratio
0.00
EPS
$0.00
Beta
0.99
52W High
$10.08
52W Low
$4.26
50-Day MA
$5.96
200-Day MA
$7.05
Dividend Yield
—
Profit Margin
0.19%
Forward P/E
81.30
PEG Ratio
—
About Xeris Pharmaceuticals Inc
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Fundamentals
| Revenue (TTM) | $291.85M |
| Gross Profit (TTM) | $249.28M |
| EBITDA | $37.05M |
| Operating Margin | 19.60% |
| Return on Equity | -617.00% |
| Return on Assets | 4.40% |
| Revenue/Share (TTM) | $1.82 |
| Book Value | $0.08 |
| Price-to-Book | 76.80 |
| Price-to-Sales (TTM) | 3.56 |
| EV/Revenue | 4.106 |
| EV/EBITDA | 28.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 42.80% |
| Shares Outstanding | $172.63M |
| Float | $163.61M |
| % Insiders | 3.36% |
| % Institutions | 59.24% |
Historical Volatility
HV 10-Day
44.25%
HV 20-Day
39.45%
HV 30-Day
46.11%
HV 60-Day
46.21%
HV Rank
21.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($11.14 target)
1
Strong Buy5
Buy1
HoldData last updated: 4/30/2026